PGEN
Precigen, Inc.
NASDAQ · USHealthcareBiotechnology
$5.07+2.42%
Price as of Jul 20, 2026
PGEN profitability
Precigen, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 75.6%
- EBITDA margin
- -617.8%
- EBIT margin
- -297.2%
- Net margin
- -647.0%
- Free cash flow margin
- -372.1%
Returns
- Return on equity
- -1010.2%
- Return on assets
- -147.5%
- Return on invested capital
- -79.3%
- Asset turnover
- 0.21x
Cash efficiency
- Cash from operations
- -$115.3M
- Cash per share
- $0.16
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.